Ontology highlight
ABSTRACT:
SUBMITTER: Ravandi F
PROVIDER: S-EPMC4081440 | biostudies-literature | 2011 Oct
REPOSITORIES: biostudies-literature
Ravandi Farhad F O'Brien Susan S Jorgensen Jeffrey J Pierce Sherry S Faderl Stefan S Ferrajoli Alessandra A Koller Charles C Challagundla Pramoda P York Sergernne S Brandt Mark M Luthra Rajyalakshmi R Burger Jan J Thomas Deborah D Keating Michael M Kantarjian Hagop H
Blood 20110805 14
We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg/m² given IV over 2 hours daily for 5 days was followed ∼ 1 month later with rituximab 375 mg/m² IV weekly for 8 weeks. Responses were recorded and BM minimal residual disease (MRD) was evaluated after the completion of rituximab. Thirty-six patients have been treated including 5 with HCLv. Median age was 57 ...[more]